Treatment of Allergic Asthma with Fenretinide Formulation (LAU-7b) Downregulates ORMDL Sphingolipid Biosynthesis Regulator 3 (Ormdl3) Expression and Normalizes Ceramide Imbalance

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73601246" target="_blank" >RIV/61989592:15110/20:73601246 - isvavai.cz</a>

Výsledek na webu

<a href="https://obd.upol.cz/id_publ/333181132" target="_blank" >https://obd.upol.cz/id_publ/333181132</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1124/jpet.119.263715" target="_blank" >10.1124/jpet.119.263715</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Treatment of Allergic Asthma with Fenretinide Formulation (LAU-7b) Downregulates ORMDL Sphingolipid Biosynthesis Regulator 3 (Ormdl3) Expression and Normalizes Ceramide Imbalance

Popis výsledku v původním jazyce

Allergic asthma causes global health burdens as it affects millions of people worldwide. Being a complex disease, in addition to environmental exposures, several genetically controlled factors greatly influence the predisposition and severity of allergic asthma (Burbank et al. 2017). Genome wide association studies (GWAS) have highlighted the 17q21 locus, which contains several susceptibility genes including Zona pellucida binding protein 2 (ZPBP2) and ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3), on human chromosome 17 and their orthologs Zpbp2 and Ormdl3 on mouse chromosome 11, as a well-established susceptible locus for airway hyperresponsiveness (AHR) (Moffatt et al. 2007). The 17q21 locus importance was evaluated in an ethnically diverse population but ethnic-based differences were not found (Kothari et al. 2018).

Název v anglickém jazyce

Treatment of Allergic Asthma with Fenretinide Formulation (LAU-7b) Downregulates ORMDL Sphingolipid Biosynthesis Regulator 3 (Ormdl3) Expression and Normalizes Ceramide Imbalance

Popis výsledku anglicky

Allergic asthma causes global health burdens as it affects millions of people worldwide. Being a complex disease, in addition to environmental exposures, several genetically controlled factors greatly influence the predisposition and severity of allergic asthma (Burbank et al. 2017). Genome wide association studies (GWAS) have highlighted the 17q21 locus, which contains several susceptibility genes including Zona pellucida binding protein 2 (ZPBP2) and ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3), on human chromosome 17 and their orthologs Zpbp2 and Ormdl3 on mouse chromosome 11, as a well-established susceptible locus for airway hyperresponsiveness (AHR) (Moffatt et al. 2007). The 17q21 locus importance was evaluated in an ethnically diverse population but ethnic-based differences were not found (Kothari et al. 2018).

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

—

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

ISSN

0022-3565

e-ISSN

—

Svazek periodika

373

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

476-487

Kód UT WoS článku

000551159700015

EID výsledku v databázi Scopus

2-s2.0-85085157460